Ardelyx Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Ardelyx wird ein jährliches Gewinn- und Umsatzwachstum von 60.7% bzw. 32.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 60.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 46.5% betragen.

Wichtige Informationen

64.0%

Wachstumsrate der Gewinne

64.2%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.7%
Wachstumsrate der Einnahmen	30.2%
Zukünftige Eigenkapitalrendite	25.4%
Analystenabdeckung	Good
Zuletzt aktualisiert	23 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 04

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 24

Recent updates

Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook

Jul 13

Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge

Jul 05

Ardelyx: Strong Execution, Fairly Valued

May 10

Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 04

Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)

May 03

Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing

Apr 17

Ardelyx Shrugs Off 'Mixed' Q4 Earnings

Mar 13

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 24

Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance

Feb 20

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Aug 03

Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

Jul 31

Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now

Apr 17

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Mar 30

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Dec 14

What To Expect For Ardelyx In The Coming Month

Oct 18

Ardelyx: Potential For Growth, But Must Strengthen Its Financial Position

Oct 04

Ardelyx secures $20M financial deal with HealthCare Royalty on tenapanor potential sale

Jun 30

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:ARDX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	502	137	160	165	8
12/31/2025	349	2	7	110	10
12/31/2024	243	-79	-73	-47	10
3/31/2024	159	-66	-81	-81	N/A
12/31/2023	124	-66	-90	-90	N/A
9/30/2023	134	-27	-67	-67	N/A
6/30/2023	83	-56	-71	-71	N/A
3/31/2023	63	-66	-87	-87	N/A
12/31/2022	52	-67	-70	-70	N/A
9/30/2022	9	-114	-124	-124	N/A
6/30/2022	5	-135	-133	-133	N/A
3/31/2022	4	-153	-137	-136	N/A
12/31/2021	10	-158	-154	-153	N/A
9/30/2021	11	-151	-133	-131	N/A
6/30/2021	12	-125	-118	-116	N/A
3/31/2021	13	-105	-102	-101	N/A
12/31/2020	8	-94	-82	-81	N/A
9/30/2020	8	-85	-75	-75	N/A
6/30/2020	8	-91	-76	-76	N/A
3/31/2020	6	-91	-85	-85	N/A
12/31/2019	5	-95	-77	-76	N/A
9/30/2019	3	-103	-84	-84	N/A
6/30/2019	0	-104	-91	-90	N/A
3/31/2019	0	-100	-81	-80	N/A
12/31/2018	3	-91	-71	-70	N/A
9/30/2018	45	-53	-47	-47	N/A
6/30/2018	44	-50	-40	-39	N/A
3/31/2018	44	-53	-47	-45	N/A
12/31/2017	42	-64	N/A	-65	N/A
9/30/2017	N/A	-106	N/A	-97	N/A
6/30/2017	N/A	-114	N/A	-102	N/A
3/31/2017	N/A	-117	N/A	-103	N/A
12/31/2016	N/A	-112	N/A	-93	N/A
9/30/2016	N/A	-98	N/A	-87	N/A
6/30/2016	N/A	-87	N/A	-75	N/A
3/31/2016	18	-50	N/A	-80	N/A
12/31/2015	24	-30	N/A	-72	N/A
9/30/2015	30	-16	N/A	-54	N/A
6/30/2015	38	2	N/A	-48	N/A
3/31/2015	29	-6	N/A	6	N/A
12/31/2014	32	-3	N/A	13	N/A
9/30/2014	34	-4	N/A	28	N/A
6/30/2014	33	-5	N/A	34	N/A
3/31/2014	31	-7	N/A	5	N/A
12/31/2013	29	-7	N/A	2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ARDX wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: ARDX wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: ARDX wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: ARDXDie Einnahmen des Unternehmens (32.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: ARDXDie Einnahmen des Unternehmens (32.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ARDXDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (25.4%)

Ardelyx Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 18%

Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Forecast breakeven date pushed back to 2026

Price target increased by 7.1% to US$13.39

Consensus EPS estimates fall by 95%, revenue upgraded

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Recent updates

Ardelyx, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook

Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge

Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell Small Cap Comp Value Index

Ardelyx, Inc. Chooses Not to File for TDAPA to Preserve Patient Access to XPHOZAH

Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial Officer

President recently sold US$246k worth of stock

Insider recently sold US$782k worth of stock

Ardelyx: Strong Execution, Fairly Valued

Consensus revenue estimates increase by 18%

Insider notifies of intention to sell stock

Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date pushed back to 2026

Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)

President notifies of intention to sell stock

Ardelyx, Inc., Annual General Meeting, Jun 14, 2024

Ardelyx, Inc. to Report Q1, 2024 Results on May 02, 2024

Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing

Price target increased by 7.1% to US$13.39

Ardelyx, Inc. Announces the Appointment of Mike Kelliher as Executive Vice President, Corporate Development and Strategy

Insider notifies of intention to sell stock

Ardelyx Shrugs Off 'Mixed' Q4 Earnings

Ardelyx, Inc. announced that it has received $50 million in funding

Consensus EPS estimates fall by 95%, revenue upgraded

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Full year 2023 earnings: EPS misses analyst expectations

Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance

Ardelyx, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Ardelyx's XPHOZAH Still An Afterthought To The Pros

Consensus estimates of losses per share improve by 10%

Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement

Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price

Key Executive notifies of intention to sell stock

Price target increased by 9.5% to US$9.94

Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt

Insider notifies of intention to sell stock

Ardelyx Announces Departure of Geoffrey Block as Board Member

Ardelyx, Inc. Announces XPHOZAH(R) (tenapanor) Now Available in the United States

Consensus revenue estimates increase by 16%

Ardelyx Shares Positive Data from Studies of Xphozah®? (Tenapanor) At Asn Kidney Week 2023

Price target increased by 10% to US$9.36

Ardelyx, Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ardelyx, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Insufficient new directors

Ardelyx, Inc. Shares Positive Data on Symptom Response During Treatment with IBSRELA®? (tenapanor) for IBS-C and Hosts IBS-C Product Theater at ACG 2023

Ardelyx, Inc. Announces FDA Approval of XPHOZAH (tenapanor), a First-In-Class Phosphate Absorption Inhibitor

Ardelyx, Inc. Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

Consensus revenue estimates increase by 17%

New major risk - Shareholder dilution

Price target increased by 7.1% to US$7.58

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

Ardelyx, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Insider notifies of intention to sell stock

Forecast breakeven date pushed back to 2025

Ardelyx, Inc. Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH(R)

Consensus EPS estimates fall by 47%, revenue upgraded

Price target increased by 7.6% to US$7.08

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Consensus revenue estimates increase by 29%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)

Forecast to breakeven in 2024

Ardelyx Provides Update on FDA Appeal for XPHOZAH (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis